Trial Profile

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Lichen planus
Focus First in man; Therapeutic Use

Most Recent Events

14 Feb 2025 Results published in the Archives of Dermatological Research
12 Mar 2024 Results evaluating the efficacy of baricitinib in cutaneous LP, presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Results assessing the repurposed and optimized the modified Composite Assessment of Index Lesion Severity (mCAILS) for LP using data from NCT03697460 trial and validated the optimized lichen planus CAILS (lpCAILS) using data from NCT05188521 trial, presented at the American Academy of Dermatology annual Meeting 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com